# Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA

> **NCT02562443** · PHASE3 · TERMINATED · sponsor: **Traws Pharma, Inc.** · enrollment: 372 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- MDS
- Refractory Anemia With Excess Blasts
- RAEB

## Interventions

- **DRUG:** rigosertib
- **DRUG:** Any approved or standard-of-care therapy
- **DRUG:** best supportive care (BSC)
- **DRUG:** best supportive care (BSC)

## Key facts

- **NCT ID:** NCT02562443
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-02
- **Primary completion:** 2020-07-26
- **Final completion:** 2021-07-26
- **Target enrollment:** 372 (ACTUAL)
- **Why stopped:** Top line analysis indicated that the study had failed to achieve its primary endpoint.
- **Last updated:** 2022-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02562443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02562443, "Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02562443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*